<DOC>
	<DOCNO>NCT01354171</DOCNO>
	<brief_summary>This multi-centre , prospective , randomized phase III trial determine multi-parametric Magnetic Resonance Imaging ( MRI ) improve selection patient eligible active surveillance well detection clinically significant cancer .</brief_summary>
	<brief_title>Active Surveillance Magnetic Resonance Imaging Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>histological confirmation adenocarcinoma prostate candidate active surveillance ( favourable risk prostate cancer ) define follow : Clinical stage T1b , T1c , T2a T2b time diagnosis Clinical ( diagnostic biopsy ) Gleason sum &lt; 6 PSA &lt; 10.0 ng/ml ( ug/L ) Previous treatment prostate cancer include surgery ( exclude biopsy ) , radiation therapy , hormonal therapy ( e.g . megestrol , medroxyprogesterone , cyproterone , DES ) , glucocorticoid ( except inhale topical ) , LHRH analogue ( e.g . Leuprolide , goserelin ) , ketoconazole , nonsteroidal antiandrogens ( e.g . bicalutamide , flutamide ) and/or 5Î±reductase inhibitor within 3 month randomization Planned antiandrogen therapy Inability undergo TRUS biopsy Inability undergo multiparametric MRI</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>active surveillance</keyword>
	<keyword>low risk prostate cancer</keyword>
</DOC>